Search

Displaying results 601 - 610 of 2959 in total
  1. Drug

    Thallous chloride

    go.drugbank.com/drugs/DB09316
    ApprovedWithdrawn

    Thallous chloride (also known as Thallium(I) chloride) is a colourless solid intermediate in the isolation of thallium from its ores. It is created from the treatment of thallium(I) sulfate with hydrochloric acid. This solid crystallizes...

  2. Drug

    Remdesivir

    go.drugbank.com/drugs/DB14761
    ApprovedInvestigational

    [L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020,[L13236] remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22 … [L39640] Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.[L22619]

  3. Drug

    Telmisartan

    go.drugbank.com/drugs/DB00966
    ApprovedInvestigational

    Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinit...

    Mixtures: Nra-telmisartan/hctz, Nra-telmisartan/hctzProducts: Nra-telmisartan, TELMISARTAN EG
  4. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.

  5. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929] … [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.

  6. Drug

    Fluoroestradiol F-18

    go.drugbank.com/drugs/DB15690
    ApprovedInvestigational

    [A203912] Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna. … [L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression

  7. Drug

    Norfloxacin

    go.drugbank.com/drugs/DB01059
    ApprovedInvestigational

    A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.

    Products: NORFLOXACINA EG, NORMED 400 - U
  8. Drug

    Everolimus

    go.drugbank.com/drugs/DB01590
    ApprovedInvestigational

    Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a simi...

    Products: EVEROLIMUS EG
  9. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953]

  10. Drug

    Fusidic acid

    go.drugbank.com/drugs/DB02703
    ApprovedInvestigational

    (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.

    Mixtures: M-FURO FA %0.1 + %2 KREM, 30 G